Ohio State, ETCR strike license deal on resistant canine hookworms

The Ohio State University College of Veterinary Medicine and East Tennessee Clinical Research, or ETCR, said they’ve signed an exclusive license agreement aimed at speeding development of new therapies for multidrug-resistant canine hookworms. Under the deal, ETCR gets rights to use and distribute licensed multidrug-resistant Ancylostoma caninum larvae for approved research, and to run commercial efficacy studies for animal health companies. Ohio State said the larvae were isolated and propagated from a clinical case at its Veterinary Medical Center that failed multiple courses of FDA-approved dewormers. The announcement was published April 20, 2026. (vet.osu.edu)

Why it matters: For veterinary professionals, this is less about a single deal and more about infrastructure. The American Association of Veterinary Parasitologists recently said A. caninum has developed resistance to all anthelmintic classes registered for dogs in North America, and that multidrug-resistant cases have spread widely in the U.S. and have also been found in Canada. That makes access to characterized resistant isolates important for drug screening, study design, and eventually regulatory submissions. It also lands as hookworm prevalence and awareness remain uneven in practice, even though veterinarians are the first line for diagnosis, retesting, prevention counseling, and reducing zoonotic risk. (sciencedirect.com)

What to watch: Watch for ETCR-led efficacy studies, potential partnerships with animal health companies, and whether this platform helps move new or repurposed hookworm therapies toward regulatory review. (vet.osu.edu)